Ranbaxy receives USFDA nod for Amlodipine Besylate tablets - Hindustan Times
close_game
close_game

Ranbaxy receives USFDA nod for Amlodipine Besylate tablets

PTI | By, Mumbai
Jun 20, 2007 10:12 PM IST

Ranbaxy Laboratoris says it has received tentative US Food and Drug Administration approval to market its anti-hypertension tablets, Amlodipine Besylate, in the US.

Country's biggest pharmaceutical firm Ranbaxy Laboratories on Wednesday said it has received tentative US Food and Drug Administration (USFDA) approval to market its anti-hypertension tablets, Amlodipine Besylate, in the US.

HT Image
HT Image

Ranbaxy has received the approval for the tablets in 2.5 mg, 5 mg and 10 mg strengths, the company said in a communique to the Bombay Stock Exchange.

Hindustan Times - your fastest source for breaking news! Read now.

According to IMS-MAT data for March 2007, total annual sales for Amlodipine Besylate was 2.79 billion dollars.

"We are pleased to receive this tentative approval for Amlodipine Besylate Tablets. This product represents a future opportunity for Ranbaxy and will be launched following final approval from the FDA," Ranbaxy Pharmaceuticals Inc (RPI), USA, Vice President (Sales and Marketing) Jim Meehan said.

Amlodipine Besylate tablets are indicated for the treatment of hypertension and may be used alone or in combination with other anti-hypertension agents.

The drug is also indicated for the symptomatic treatment of chronic stable angina and may be used alone or in combination with other antianginal agents.

RPI is a wholly-owned subsidiary of Ranbaxy Laboratories. RPI is engaged in the sale and distribution of generic and branded prescription products in the US.

Shares of Ranbaxy dipped 1.91 per cent and closed at Rs 351.85 on the BSE.

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away!- Login Now!
Stay informed on Business News along with Gold Rates Today, India News and other related updates on Hindustan Times Website and APPs
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On